SARS News and Research

RSS

mRNA COVID vaccines prove effective in the elderly

Coronavirus disease 2019 (COVID-19) proved extremely difficult to control once it entered a country – while there were a few success stories such as New Zealand, most countries ended up resorting to lengthy and economically painful lockdowns, among other restriction measures.

27 Sep 2021

Study shows prior COVID-19 and vaccination protects elderly against variants

In order to qualify the risk posed to the elderly, researchers from MUSE University in France began to investigate data from nursing homes that had faced outbreaks from variants of concern. Their work can be found on the medRxiv* preprint server while awaiting peer review.

27 Sep 2021

COVID-19 vaccine effectiveness barely affected by Delta variant, research suggests

Has the Delta (B.1.617.2) variant reduced vaccine effectiveness? If you ask Ian Foster of Argonne National Laboratory and colleagues, the answer is not really. New research published in the preprint medRxiv* server suggests vaccines approved in the United States are stable and well-performing.

27 Sep 2021

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Japanese scientists created "elite" antibodies that defeat various coronavirus variants even at an extremely low dose through a new method that accelerated the months-long process of finding such extraordinary antibody candidates to just ten days.

27 Sep 2021

Study reveals surfaces of SARS-CoV-2 spike most resistant to antibody escape

A team of international scientists has formed a consortium to map the epitope landscape of a range of therapeutic monoclonal antibodies on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the scientists characterized the neutralization potency of these antibodies and have investigated how emerging viral variants with spike mutations can impact antibody-mediated neutralization. They have recently published the consortium findings in the journal Science.

27 Sep 2021

A review of drugs harmful in COVID-19

In a new study, researchers investigate a number of drugs that are believed to potentially worsen outcomes in patients with COVID-19.

26 Sep 2021

Study shows SARS-CoV-2 breakthrough infections 18-fold lower than rate of infections among unvaccinated

In a recent study, researchers conducted a pilot study to assess the prevalence and features of VBTs through the use of sequencing and case data.

26 Sep 2021

Study to determine the characteristics and outcome of patients hospitalized with COVID-19

The study summarized the clinical presentation and demographic features of patients who were hospitalized with COVID-19.

26 Sep 2021

Factors predicting vaccine hesitancy in India

A recent study discusses vaccine hesitancy in India, which is one of the most populous countries in the world.

26 Sep 2021

Vaccine hesitancy and vaccination passports – a Japanese study

A new study from Keio University, Japan, provides an evaluation of the effectiveness of relaxing public interactions following vaccination against COVID-19.

26 Sep 2021

Childhood asthma is not a risk factor for COVID-19

A new study provides new insights on the association of childhood asthma and COVID-19.

26 Sep 2021

Survivors of domestic violence and abuse more likely to contract COVID-19

Women with general practitioner (GP) recorded exposure to domestic abuse or violence were at an increased risk of contracting COVID-19 during the first two waves of the pandemic in the UK, finds a new study led by the University of Birmingham.

25 Sep 2021

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19.

25 Sep 2021

Penn scientists win 2021 Lasker Award for the discovery of therapeutic mRNA technology

As mRNA-based SARS-CoV-2 vaccines are deployed to protect hundreds of millions of people across the world and point the way to end the deadly global COVID-19 pandemic, the University of Pennsylvania scientists whose prescient discovery science effort laid the foundation for swift vaccine development have been awarded the 2021 Lasker~DeBakey Clinical Medical Research Award.

24 Sep 2021

SARS News and Research

mRNA COVID vaccines prove effective in the elderly

Study shows prior COVID-19 and vaccination protects elderly against variants

COVID-19 vaccine effectiveness barely affected by Delta variant, research suggests

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Study reveals surfaces of SARS-CoV-2 spike most resistant to antibody escape

A review of drugs harmful in COVID-19

Study shows SARS-CoV-2 breakthrough infections 18-fold lower than rate of infections among unvaccinated

Study to determine the characteristics and outcome of patients hospitalized with COVID-19

Factors predicting vaccine hesitancy in India

Vaccine hesitancy and vaccination passports – a Japanese study

Childhood asthma is not a risk factor for COVID-19

Survivors of domestic violence and abuse more likely to contract COVID-19

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Penn scientists win 2021 Lasker Award for the discovery of therapeutic mRNA technology

WHO experts recommend antibody treatment for two specific groups of patients with covid-19

Further evidence of safety and efficacy of mRNA-1273 vaccine in preventing symptomatic COVID-19 and SARS-CoV-2 infection

Inactivated egg-based Newcastle disease virus vaccine expressing SARS-CoV-2 spike protein

COVID-19 vaccination status among US college students

Scientists publish a detailed map of where human antibodies bind to SARS-CoV-2

Presumed immunity in US remains below the threshold sufficient to disrupt SARS-CoV-2 transmission

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News